A randomized trial is conducted to evaluate the efficacy of a new cholesterol lowering medication. The primary outcome is incident coronary artery disease. Participants are free of coronary artery at the start of the study and randomized to receive either the new medication or a placebo. Participants are followed for a maximum of 10 years for the development of coronary artery disease. The following data are observed.
1) Compute the Relative Risk of coronary artery disease in patients receiving the new medication as compared to placebo.
Relative Risk =
2) Compute the Odds Ratio of coronary artery disease in patients receiving the new medication as compared to placebo.
Odds Ratio =
Number of participants Number with coronary artery disease
Cholesterol medication 800 56
Placebo 800 84